TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of cystic fibrosis participants with NTM isolates matching environmental isolates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of gd T-cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cancer-related stress reactions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: UHDRS-motor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Desire domain of the Female Sexual Function Index (FSFI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composition of Stool Micro Biome Diversity and Phylogenetic Distribution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Indicators of Inflammation and Injury (TNF Alpha, IL-6)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Resting Energy Expenditure (REE) and Metabolic Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Erythema in photodamaged and photoprotected skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Human Beta Defensin 2 (DEFB4) Fold Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wheal Response in photodamaged and photoprotected skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Heart Rate and Blood Pressure Double Product
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical Global Impression of Change-Clinician Rated Score (CGIC-C)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Connors Adult Attention Deficit Hyperactivity Disorder (ADHD) Rating Scale-Long Form (CAARS-L) Inattention/Memory Subscale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frontal Systems Behavioral Scale (FrSBe) Executive Function Subscore
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Area under the plasma concentration time profile from time zero to the time of last quantifiable concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal Elimination half life (t1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Short Form-36 Health Survey (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Early bactericidal activity (EBA) of telacebec (Q203)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: first main vascular event
Endpoint domain: Mortality/survival
Primary endpoint: Change in Subjective Well-Being (Affect)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Subjective Well-Being (Life Satisfaction)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Subjective Well-Being (Eudaimonic Well-Being)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of AEs/SAEs/Side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Change in knowledge of end-stage renal disease treatments
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Liver to muscle signal intensity ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T2* calculation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver iron concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Mean Diffusivity values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinical function profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rotavirus hospitalization rates
Endpoint domain: Mortality/survival
Primary endpoint: Seattle Angina Questionnaire Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: proportion of patients with healed esophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Frequency of insulin use
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Ki(cer) of [18 fluorine(F)]DOPA PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of first event of stroke and/or systemic embolism
Endpoint domain: Mortality/survival
Primary endpoint: Construct validity
Endpoint domain: General outcomes
Primary endpoint: Time within range 3.9 - 10 mmol/l
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: change in reading ability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Correct size of PPH Butterfly
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRR assessed by investigators per the 2014 Lugano classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Duration of CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Device Success
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of device and/or procedure related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Effectiveness of implant measured through symptom improvement (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tumor marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: inflammatory level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: immunological factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Correlation between skin test result and food challenge result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite of Major Adverse Cardiovascular Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Classification of prostate cancer risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants negative by RT-PCR for the virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of participants with lung condition change assessed with X-ray
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: satisfaction with therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Level of enriched IFN-γ+ T-cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: mean monthly seizure frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Symptom and Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of retrieved lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Daily Average Pain Score Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Suicidal Ideation and Suicidal Behavior
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Daily Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Presence of Cardiac arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hospitalizations and Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants With Clinical Laboratory Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Vital Sign Abnormalities Reported as TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Improved underarm odor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minutes of Exercise Per Week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Test Scores on Knowledge of Course Content
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Reduction in the Size of Measurable Metastatic Tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thyroid hormones (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroid hormones (FT4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Health-Related Quality-of-Life (PCOS Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean Plasma Pharmacokinetic Parameters of PLX3397
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Drospirenone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of Ethinyl Estradiol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Levels of Efavirenz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intra-operative identification of tattooed lymph node(s)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of CP-CML patients remaining on dasatinib treatment
Endpoint domain: Mortality/survival
Primary endpoint: Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Level of methylation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of expression of Genomic Imprinting (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of expression of Transposable Elements (TE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) assessed by dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with adverse events (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of subjects with serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Dopamine Active Transporter Binding Potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortisol Output in Response to a Stress Manipulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Cortisol Reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Drug related dose limiting toxicities (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Major Depression post-stroke
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of pathogenic or likely pathogenic variants of BRCA1/2 and other genetic susceptibility genes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Stair-climb power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in total annualized factor consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total plasmatic bilirubin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of non-CABG major and minor bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Three-minute visual blur profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Acceptability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fat percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Skeletal muscle index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: A body shape index (ABSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of grade 3, 4, & 5 adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum Serum Concentration (Cmax) of Durvalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimum Serum Concentration (Cmin) of Durvalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Serum Concentration-Time Curve (AUC) From Zero to 14 (AUC 0-14) of Durvalumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent symptomatic intracerebral hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Recurrence Free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of non melanoma skin cancers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Area under the concentration-time curve of ranitidine in plasma (AUC0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of ranitidine in plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of HPV DNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Difference of Predictive A1c level from CGM data and Real A1c level from EMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Lower-Extremities Fugl-Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Age difference in years between donor and recipient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Program Satisfaction Ratings
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Intervention Session Attendance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Feasibility of the Intervention (Retention)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Postprandial blood glucose responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of recurrent UTIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: IL-6 Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Week 1 in Leukocyte Population at Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From 1 Week in Relative Cell Adhesion Response of PMNs at Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Week 1 in Relative Oxidative Response of PMNs at Week 5
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: PTSD Symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: TNF-α measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: lesions response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sustained Virological Response at 12 weeks post treatment completion (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of MACCE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to establish full enteral feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to stop parenteral nutrition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Day of onset of weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Type of placental and umbilical cord abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Wound healing assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Quality of life using questionnaires EORTC QLQ-30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Quality of life using questionnaires EORTC QLQ-MY20
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Rate of minimal residual disease (MRD) negative response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prediction of prostate cancer using MRI methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Symptoms of Mitochondrial diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of good quality blastocyst per fertilized oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Change From Baseline in Glycosylated Haemoglobin A1c (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve From Time Zero Extrapolated to Infinite Time (AUC[INF])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Plasma Concentration (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute intravascular volume loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline PHQ9 at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline DASS-21 at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline IES-R at 12 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delay of a subsequent pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change from Baseline in the Dizziness Handicap Inventory (DHI)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of follicles per cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Physical activity profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration vs time curve from zero to infinity after single dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum drug concentration in plasma after single dose administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability as determined by adverse events monitoring
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Apnea-hypopnea Index (AHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in post operative radiographic evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2D Radiographic Healing at 12 Months Follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 3D Radiographic Healing at 12 Months Follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: 20% improvement in American College of Rheumatology Criteria (ACR 20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate within the treated liver lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline on the Hamilton Anxiety Rating Scale (HAM-A)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on the Liebowitz Social Anxiety Scale (LSAS)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change from baseline on the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from baseline on the Clinician-Administered PTSD Scale (CAPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The total number of panic attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lichen Planopilaris Activity Index (LLPAI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response Rate (Complete Response, Partial Response, or Hematologic Improvement)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Lipid Phenotyping
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Analysis of immune cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Analysis of cytokine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hb concentration ≥ 10.0g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: increase in Hb concentration ≥ 1.0g/dL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: 10 meter walking test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes